RxDoctor Payments Data

Yohannes Goite

Pulmonary Disease · Winchester, VANPI 1518317254

Payments from drug & device makers

$241in general payments, 2019–2025

Across 9 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$58
  • Pulmonx Corporation$52
  • Gilead$31
  • Inspire Medical Systems, Inc.$28
  • Pfizer$25
  • AstraZeneca$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$241 in reported general payments places this provider in the 25th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$112,574
Medicare patients
506
Services billed
1,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$166,751
Trelegy ElliptaFluticasone/Umeclidin/Vilanter169$137,807
Prolastin CAlpha-1-Proteinase Inhibitor12$112,575
Spiriva RespimatTiotropium Bromide126$72,634
Breo ElliptaFluticasone/Vilanterol77$39,768
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$34,517
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$33,879
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$23,215
Advair HfaFluticasone Propion/Salmeterol34$14,631
SymbicortBudesonide/Formoterol Fumarate52$12,671
DuleraMometasone/Formoterol25$8,183
Incruse ElliptaUmeclidinium Bromide17$5,904
Albuterol Sulfate HfaAlbuterol Sulfate221$5,234
BreynaBudesonide/Formoterol Fumarate20$4,933
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$4,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$17$47,18898 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →